4D Molecular Therapeutics FDMT Free cash flow
Free cash flow at other companies
Other financials
Where this comes from
Calculated from 4D Molecular Therapeutics’s reported figures.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's free cash flow?
- 4D Molecular Therapeutics (FDMT) reported free cash flow of -$68.13M in Q1 2026.
- How has 4D Molecular Therapeutics's free cash flow changed year-over-year?
- 4D Molecular Therapeutics's free cash flow decreased by 40.8% year-over-year, from -$48.39M to -$68.13M.
- What is the long-term trend for 4D Molecular Therapeutics's free cash flow?
- Over 3 years (2021 to 2024), 4D Molecular Therapeutics's free cash flow has grown at a 20.9% compound annual growth rate (CAGR), from -$78.24M to -$138.37M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.